Critical Path Institute (C-Path)

Have questions about some achievements C-Path has accomplished? Whether you’re curious about how we collaborate with stakeholders, or how we’re accelerating the development of new treatments, our FAQs section is a valuable resource designed to give you the insights you need. Have a question we haven’t answered yet? Don’t hesitate to reach out—we’re always here to help and provide guidance. You can find more questions and answers on C-Path's website under FAQS: c-path.org/faqs. #C-Path #FAQs #DrugDevelopment

Day 2 of #CGIC2024 included an impactful session led by FDA's Michelle Campbell, and C-Path's Director of Advocacy, Thom Hart. The panel discussed: "Living Experiences in Action: Advocacy Update Across Rare Diseases."  Key Highlights from this session included: - Advocacy ensures future generations avoid past struggles.  - Involvement in advocacy organizations enhances patient representation.  - Incorporating those with lived experience in trial design is essential. - Collaboration among stakeholders can improve patient outcomes.  Watch the recording now: https://lnkd.in/gqkkFEvm #CPath #Advocacy #DrugDevelopment #RareDisease

Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/gCNMgWsM For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience

Dive into this session led by C-Path experts, Joe Hedrick, Executive Director of the Type 1 Diabetes Consortium and Sakshi Sardar, Senior Director of Digital and Precision Medicine as they explore "Transformative Tools to Capture Early Stages of Disease: Digital Health Technologies, Making the Invisible, Visible." Digital health technologies are revolutionizing drug development by unveiling the early, often hidden stages of diseases. These tools are pivotal in enhancing patient outcomes, streamlining drug development, and advancing healthcare delivery. Discover how DHTs are reshaping the future of medicine. Catch the full session here: https://lnkd.in/g6y7x5CA #CPath #InnovationInMedicine #DigitalHealth #DrugDevelopment #HealthcareTransformation #Type1Diabetes #CGIC2024

Did you know that you can now donate to C-Path using the Combined Federal Campaign? Are you a Federal employee or retiree? Then GIVE HAPPY to us through CFC using charity code #28364. One of the great benefits of the CFC is that you can give though payroll deduction or through your retiree annuity, giving a little each pay period and supporting our mission all year long.  #CPath #CFC #Donate #DrugDevelopment 

Have questions about some achievements C-Path has accomplished? Whether you’re curious about how we collaborate with stakeholders, or how we’re accelerating the development of new treatments, our FAQs section is a valuable resource designed to give you the insights you need. Have a question we haven’t answered yet? Don’t hesitate to reach out—we’re always here to help and provide guidance. You can find more questions and answers on C-Path's website under FAQS: c-path.org/faqs. #C-Path #FAQs #DrugDevelopment

Have questions about some achievements C-Path has accomplished? Whether you’re curious about how we collaborate with stakeholders, or how we’re accelerating the development of new treatments, our FAQs section is a valuable resource designed to give you the insights you need. Have a question we haven’t answered yet? Don’t hesitate to reach out—we’re always here to help and provide guidance. You can find more questions and answers on C-Path's website under FAQS: c-path.org/faqs.  #C-Path #FAQs #DrugDevelopment

#CGIC2O24 Day 2, Session 2 was moderated by C-Path's Vice President of Rare and Orphan Disease programs, Collin Hovinga. The panel discussed: "A Potential New Framework to Accelerate Drug Development for Rare Diseases."  The session emphasized the importance of data sharing in rare disease research, highlighting key initiatives and collaboration for drug development. Watch now: https://lnkd.in/gWfCksSu #CPath #RareDisease #DataSharing #DrugDevelopment

Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/gjME3Xn6 For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience

C-Path's Cheryl Coon, Vice President of the COA Program, leads a pivotal session on "Navigating Patient-Focused Drug Development (PFDD) Roadmap: Update on the Rare Disease Clinical Outcome Assessment (RD-COA) Resource." The PFDD Roadmap, developed by the FDA, is a groundbreaking strategic framework that amplifies the voices and experiences of patients throughout the drug development process. It’s designed to ensure that new therapies are both scientifically robust and truly patient-centered, aligning treatments with the needs and priorities of those they aim to help. 👉 Watch now: https://lnkd.in/gkv678Y3 #CPath #PFDD #DrugDevelopment #PatientCentered #RareDiseases #HealthcareInnovation #PatientAdvocacy #ClinicalOutcomes #FDA #HealthcareLeadership